Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The goal at TrPR is to accelerate progress towards impactful and accessible psychedelic treatments.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

DECEMBER 15, 2021

A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. “I agree with the committee that the preliminary findings from clinical trials — although still in early phases — evaluated by the panel are promising,” the decision’s author said.

Clinical Trials 52

Clinical Trials Conditions Supply Chain Environment 52

Veriheal

MAY 3, 2022

a necessary question to address as medical marijuana becomes more accessible. Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. Daily Cannabis Use as a Disqualifier.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

MAY 29, 2022

The grand opening event and reception invited investors, stakeholders and the residents of Princeton to take a tour through the facilities. Businesses have been recently receiving approval from Health Canada to farm psychedelic mushrooms, make psilocybin and sell the compound to drug-makers, or to doctors to give to patients.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). Petition for Review.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. In one particular group, all patients showed consistent results across multiple genomic analyses. Forward-looking statements are statements that relate to future, not past, events.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. Licensed wholesalers will be able to import larger quantities of cannabis-based products, and hold supplies for future use by patients with prescriptions, according to a government release.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Law Report

JANUARY 19, 2022

GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen’s methods has already been used in clinical trials for development of therapeutic products. “A primary application for psychedelics is to support psychotherapy for treatment of mental health conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Veriheal

JUNE 7, 2021

Note: Veriheal does not support illegally consuming therapeutic substances like MDMA but acknowledges that it transpires because of the current illicit status of both, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.

Therapy 92

Therapy Treatment Conditions Clinical Trials 92

SpeedWeed

AUGUST 4, 2021

For the first time, he was a patient and not a criminal. This event saw doctors and researchers from all over the world presenting the scientific and clinical studies surrounding the medical benefits of cannabis. . They presented case studies about patients who have had incredible success from their cannabis treatments.

Chronic Pain 52

Chronic Pain Research and Development Medicine Supply Chain 52

Cannabis Law Report

JANUARY 13, 2020

We are proud of the positive impact this medicine has already had on thousands of patients and believe that this past year provides a compelling foundation for continued success in 2020,” said Justin Gover, GW’s Chief Executive Officer. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is the largest national chain of ketamine infusion clinics in the United States and will add to Delic’s existing portfolio of two clinics operated by Ketamine Infusion Centers in California and Arizona , cementing its position as the leading and largest health provider in the country.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

DECEMBER 7, 2021

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., The patent will be issued on January 11, 2022. President, Director and Chief Medical Officer of MyMD. 2 Goates et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

The Cannigma

MARCH 25, 2021

In nursing school, I wrote my dissertation on the role of the nurse when caring for patients using cannabis therapeutically, knowing that nurses are often the first healthcare professional to whom patients disclose their cannabis use. I remain in awe of these patients to this day.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. As we prepare for a potential world-class launch of Vicineum, I strongly believe that these leaders will not only bring diverse and invaluable expertise to our team but will also drive the Company to continue executing our mission to save and improve the lives of patients with cancer.”.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market.

Therapy 52

Therapy Research and Development Business Access 52

The Cannigma

DECEMBER 12, 2022

Turning down activity in the DMN allows better access to new areas of the brain, which can boost creativity and improve problem solving. Using integration or psychotherapy along with these medicines allows patients to incorporate the positive effects permanently. As such, there have been numerous clinical trials using ketamine.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

DECEMBER 21, 2021

This service is available to businesses, K-12 schools, universities, event venues, medical offices, hospitality groups, and more to facilitate the safe return of people to in-person environments. Yet, more than half of the people in the least developed countries lack access to electricity. DALRADA SUPPORTS WORLD INITIATIVES.

Research and Development 52

Research and Development Supply Chain Data Business 52

Veriheal

JUNE 29, 2022

The study was conducted by COMPASS Pathways , a mental healthcare company that is “dedicated to accelerating patient access to evidence-based innovation in mental health.” 233 patients with TRD from 10 countries in North America and Europe received either 1 milligram, 10 milligrams, or 25 milligrams of the COMP360 psilocybin.

Clinical Trials 104

Clinical Trials Blood Pressure Treatment Therapy 104

Project CBD

FEBRUARY 28, 2023

13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinical trials seems to support CBD’s positive effects on nociceptive pain (i.e., Accessed July 25, 2021. Available at: [link] Accessed October 17, 2022. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

CannaMD

MARCH 8, 2020

In January of 2020, the Journal of the American College of Cardiology published a review titled Marijuana Use in Patients With Cardiovascular Disease. Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. a heart attack). population, has an arrhythmia.

Patients 80

Patients Marijuana Research and Development Clinical Trials 80

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

JULY 25, 2022

Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. The charity was eventually instructed to pull an advertisement for the study by the ethics committee that conditionally approved the trial.

Medicine 52

Medicine Therapy Research and Development Business 52

Project CBD

MAY 3, 2023

Dr. Goldstein has treated thousands of patients with medical cannabis. She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. I have used it in some of my patients with autism. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

JANUARY 26, 2022

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. No drug is without risks, so clinical trials have included careful investigation of possible adverse effects.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

NOVEMBER 7, 2019

Cannatrek’s Seed to Patient business model combines cutting edge cultivation expertise and world class manufacturing practices to deliver high quality medicinal cannabis oil formulations and medicinal strains of dried flowers at a significantly lower cost to patients and retailers.

Medicine 40

Medicine Patients Research and Development Clinical Trials 40

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

The Joint Blog

JUNE 2, 2020

According to a new study published in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions. Adverse events were mostly mild and resolved spontaneously. 9 -THC: 0.5mg, 1mg, or a placebo. ?

Chronic Pain 58

Chronic Pain Clinical Trials Marijuana Safety 58

The Cannigma

MAY 7, 2021

The Cannabis Enigma podcast is a co-production of The Cannigma and Americans for Safe Access. You’ve had this conversation in the US for over 20 years in some states so it’s not as if suddenly overnight, people have woken up to the discussion of cannabis and cannabis legalization and cannabis access. Music by Desca.

Supply Chain 120

Supply Chain Patients Access Hemp 120

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The review, however, did not cover patient access to medicinal cannabis. A recent study by Lintzeris et al.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JULY 15, 2022

“It’s very important from our perspective to ensure that the Australian patient gets medicine first. The first medicinal cannabis ‘mother’ plants are expected to be imported from Israel within a month, with manufacturing scheduled to begin within the first half of this year, to supply 5,000 Australian patients.

Medicine 52

Medicine Patients Media Supply Chain 52

SMPL

MAY 26, 2020

We were talking about, ‘What can we do with this?’ ” recalled Samantha Miller, who hosted the event at her split-level house, wedged between redwoods and a creek below. A headstrong biochemist, she had been growing marijuana since the age of 14 and had just quit a six-figure job to start her own cannabis testing lab.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40